Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: Reversion by antiviral treatment with pegylated IFNα and ribavirin

Clinical Immunology

Volumn 128, Issue 1, 2008, Pages 46-56

  Gonzalez, Veronica D ^a   Falconer, Karolin ^a   Michaëlsson, Jakob ^a   Moll, Markus ^a   Reichard, Olle ^a   Alaeus, Annette ^a   Sandberg, Johan K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CD1d; HCV; HIV; Interferon; NK cells; NKT cells; Viral infections

Indexed keywords

CD16 ANTIGEN; CD1D ANTIGEN; CD56 ANTIGEN; PEGINTERFERON ALPHA2A; PERFORIN; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; KINETICS; MALE; MIXED INFECTION; NATURAL KILLER CELL; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; VIRUS LOAD;

ADULT; AGED; ANTIGENS, CD56; ANTIVIRAL AGENTS; FEMALE; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON ALFA-2A; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; VIREMIA;

EID: 49949151836     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.03.521     Document Type: Article

References (56)

1. Fauci A.S., Mavilio D., and Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5 (2005) 835-843
2. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5 (2005) 215-229
3. Lodoen M.B., and Lanier L.L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18 (2006) 391-398
4. Crotta S., Stilla A., Wack A., D'Andrea A., Nuti S., D'Oro U., Mosca M., Filliponi F., Brunetto R.M., Bonino F., Abrignani S., and Valiante N.M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195 (2002) 35-41
5. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., and Abrignani S. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
6. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 (2002) 43-49
7. De Maria A., Fogli M., Mazza S., Basso M., Picciotto A., Costa P., Congia S., Mingari M.C., and Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur. J. Immunol. 37 (2007) 445-455
8. Nattermann J., Feldmann G., Ahlenstiel G., Langhans B., Sauerbruch T., and Spengler U. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55 (2006) 869-877
9. Meier U.C., Owen R.E., Taylor E., Worth A., Naoumov N., Willberg C., Tang K., Newton P., Pellegrino P., Williams I., Klenerman P., and Borrow P. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J. Virol. 79 (2005) 12365-12374
10. Morishima C., Paschal D.M., Wang C.C., Yoshihara C.S., Wood B.L., Yeo A.E., Emerson S.S., Shuhart M.C., and Gretch D.R. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43 (2006) 573-580
11. Freundt E.C., and Lenardo M.J. Interfering with interferons: hepatitis C virus counters innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17539-17540
12. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
13. Li X.D., Sun L., Seth R.B., Pineda G., and Chen Z.J. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17717-17722
14. Bandyopadhyay S., Ziegner U., Campbell D.E., Miller D.S., Hoxie J.A., and Starr S.E. Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1. Clin. Exp. Immunol. 79 (1990) 430-435
15. Bonaparte M.I., and Barker E. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104 (2004) 2087-2094
16. Fehniger T.A., Herbein G., Yu H., Para M.I., Bernstein Z.P., O'Brien W.A., and Caligiuri M.A. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J. Immunol. 161 (1998) 6433-6438
17. Kottilil S., Chun T.W., Moir S., Liu S., McLaughlin M., Hallahan C.W., Maldarelli F., Corey L., and Fauci A.S. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187 (2003) 1038-1045
18. Oliva A., Kinter A.L., Vaccarezza M., Rubbert A., Catanzaro A., Moir S., Monaco J., Ehler L., Mizell S., Jackson R., Li Y., Romano J.W., and Fauci A.S. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102 (1998) 223-231
19. Ahmad A., Morisset R., Thomas R., and Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 7 (1994) 428-437
20. Azzoni L., Papasavvas E., Chehimi J., Kostman J.R., Mounzer K., Ondercin J., Perussia B., and Montaner L.J. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity. J. Immunol. 168 (2002) 5764-5770
21. De Maria A., Fogli M., Costa P., Murdaca G., Puppo F., Mavilio D., Moretta A., and Moretta L. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol. 33 (2003) 2410-2418
22. Ziegner U., Campbell D., Weinhold K., Frank I., Rutstein R., and Starr S.E. Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. Clin. Diagn. Lab. Immunol. 6 (1999) 718-724
23. Ballan W.M., Vu B.A., Long B.R., Loo C.P., Michaelsson J., Barbour J.D., Lanier L.L., Wiznia A.A., Abadi J., Fennelly G.J., Rosenberg M.G., and Nixon D.F. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J. Immunol. 179 (2007) 3362-3370
24. Alter G., Teigen N., Davis B.T., Addo M.M., Suscovich T.J., Waring M.T., Streeck H., Johnston M.N., Staller K.D., Zaman M.T., Yu X.G., Lichterfeld M., Basgoz N., Rosenberg E.S., and Altfeld M. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106 (2005) 3366-3369
25. Hu P.F., Hultin L.E., Hultin P., Hausner M.A., Hirji K., Jewett A., Bonavida B., Detels R., and Giorgi J.V. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56-cells with low lytic activity. J. Acquir. Immune Defic. Syndr. Human Retrovirol. 10 (1995) 331-340
26. Mavilio D., Benjamin J., Daucher M., Lombardo G., Kottilil S., Planta M.A., Marcenaro E., Bottino C., Moretta L., Moretta A., and Fauci A.S. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15011-15016
27. Mavilio D., Lombardo G., Benjamin J., Kim D., Follman D., Marcenaro E., O'Shea M.A., Kinter A., Kovacs C., Moretta A., and Fauci A.S. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2886-2891
28. Godfrey D.I., and Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114 (2004) 1379-1388
29. Sandberg J.K., and Ljunggren H.G. Development and function of CD1d-restricted NKT cells: influence of sphingolipids, SAP and sex. Trends Immunol. 26 (2005) 347-349
30. Bendelac A., Savage P.B., and Teyton L. The biology of NKT cells. Annu. Rev. Immunol. 25 (2007) 297-336
31. Motsinger A., Haas D.W., Stanic A.K., Van Kaer L., Joyce S., and Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195 (2002) 869-879
32. Sandberg J.K., Fast N.M., Palacios E.H., Fennelly G., Dobroszycki J., Palumbo P., Wiznia A., Grant R.M., Bhardwaj N., Rosenberg M.G., and Nixon D.F. Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 76 (2002) 7528-7534
33. van der Vliet H.J., von Blomberg B.M., Hazenberg M.D., Nishi N., Otto S.A., van Benthem B.H., Prins M., Claessen F.A., van den Eertwegh A.J., Giaccone G., Miedema F., Scheper R.J., and Pinedo H.M. Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J. Immunol. 168 (2002) 1490-1495
34. Inoue M., Kanto T., Miyatake H., Itose I., Miyazaki M., Yakushijin T., Sakakibara M., Kuzushita N., Hiramatsu N., Takehara T., Kasahara A., and Hayashi N. Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection. J. Hepatol. 45 (2006) 190-196
35. Lucas M., Gadola S., Meier U., Young N.T., Harcourt G., Karadimitris A., Coumi N., Brown D., Dusheiko G., Cerundolo V., and Klenerman P. Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol. 77 (2003) 2251-2257
36. van der Vliet H.J., Molling J.W., von Blomberg B.M., Kolgen W., Stam A.G., de Gruijl T.D., Mulder C.J., Janssen H.L., Nishi N., van den Eertwegh A.J., Scheper R.J., and van Nieuwkerk C.J. Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin. Immunol. 114 (2005) 183-189
37. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., and Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163 (1999) 4647-4650
38. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., von Blomberg B.M., Scheper R.J., van der Vliet H.J., van den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., and Pinedo H.M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8 (2002) 3702-3709
39. Nieda M., Okai M., Tazbirkova A., Lin H., Yamaura A., Ide K., Abraham R., Juji T., Macfarlane D.J., and Nicol A.J. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103 (2004) 383-389
40. Smyth M.J., Wallace M.E., Nutt S.L., Yagita H., Godfrey D.I., and Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201 (2005) 1973-1985
41. Koziel M.J., and Peters M.G. Viral hepatitis in HIV infection. N. Engl. J. Med. 356 (2007) 1445-1454
42. Dutoit V., Ciuffreda D., Comte D., Gonvers J.J., and Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur. J. Immunol. 35 (2005) 3493-3504
43. Graham C.S., Wells A., Liu T., Sherman K.E., Peters M., Chung R.T., Bhan A.K., Andersen J., and Koziel M.J. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. Aids 20 (2006) 345-351
44. Kim A.Y., Lauer G.M., Ouchi K., Addo M.M., Lucas M., Schulze Zur Wiesch J., Timm J., Boczanowski M., Duncan J.E., Wurcel A.G., Casson D., Chung R.T., Draenert R., Klenerman P., and Walker B.D. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood 105 (2005) 1170-1178
45. Capa L., Soriano V., Garcia-Samaniego J., Nunez M., Romero M., de Mendoza C., Cascajero A., Munoz F., Gonzalez-Lahoz J., and Benito J.M. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients. Antivir. Ther. 12 (2007) 459-468
46. Soriano V., Puoti M., Sulkowski M., Cargnel A., Benhamou Y., Peters M., Mauss S., Brau N., Hatzakis A., Pol S., and Rockstroh J. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. Aids 21 (2007) 1073-1089
47. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
48. Gonzalez V.D., Bjorkstrom N.K., Malmberg K.J., Moll M., Kuylenstierna C., Michaelsson J., Ljunggren H.G., and Sandberg J.K. Application of nine-color flow cytometry for detailed studies of the phenotypic complexity and functional heterogeneity of human lymphocyte subsets. J. Immunol. Methods 330 (2008) 64-74
49. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., Alexander G.J., Cramp M.E., O'Brien S.J., Rosenberg W.M., Thomas D.L., and Carrington M. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
50. Sandberg J.K., Bhardwaj N., and Nixon D.F. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 33 (2003) 588-596
51. Sandberg J.K., Stoddart C.A., Brilot F., Jordan K.A., and Nixon D.F. Development of innate CD4+ alpha-chain variable gene segment 24 (Valpha24) natural killer T cells in the early human fetal thymus is regulated by IL-7. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 7058-7063
52. Shire N.J., and Sherman K.E. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin. Infect. Dis. 41 Suppl 1 (2005) S63-S68
53. Portales P., Reynes J., Pinet V., Rouzier-Panis R., Baillat V., Clot J., and Corbeau P. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo. Aids 17 (2003) 495-504
54. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., and Caligiuri M.A. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001) 3146-3151
55. Guidotti L.G., and Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19 (2001) 65-91
56. Moll M., Snyder-Cappione J., Spotts G., Hecht F.M., Sandberg J.K., and Nixon D.F. Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2. Blood 107 (2006) 3081-3083